Pharma Focus Asia

Astellas Pharma and Kate Therapeutics Enter into Licence Agreement for KT430

Thursday, June 08, 2023

Astellas Pharma and Kate Therapeutics announced an exclusive licence agreement for the development and commercialisation of KT430.

Under the terms of the agreement, Astellas will provide an upfront payment to Kate Therapeutics. Additionally, Kate Therapeutics stands to receive milestone payments related to development, regulatory approvals, and commercial achievements, along with royalties based on global sales. 

As part of the agreement, Astellas will gain exclusive worldwide rights to develop, manufacture, and market KT430.

This agreement between Astellas and Kate Therapeutics aims to explore and advance the development of KT430 as a potential therapy for individuals diagnosed with X-linked myotubular myopathy (XLMTM). Moreover, this will allow Astellas and Kate Therapeutics to combine the expertise and resources to evaluate the therapeutic potential of KT430 in addressing the specific challenges faced by XLMTM patients.

KT430 is a preclinical next-generation investigational gene therapy that aims to treat X-linked myotubular myopathy (XLMTM). XLMTM is indeed a serious, life-threatening, and rare neuromuscular disease characterised by extreme muscle weakness, respiratory failure, and an increased risk of early death.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024